Objective To study survival and characterize long-term functional impairments as well as health-related quality of life (HRQOL) of Lambert-Eaton myasthenic syndrome (LEMS) patients. Methods In this
Supplemental Figure 8: Fitzpatrick skin type III, acute paronychia following treatment with fibroblast growth factor receptor inhibitor, futibatinib. Bilateral thumbnails onycholytic with friability o
Patients undergoing d-rad may have the same OS and HFS as those undergoing d-CRT. Patients attributed approximately 7% of their OS to hospitalization and outpatient consultation, regardless of the tre
Purpose The increasing recognition of the complex impacts of a cancer diagnosis and its treatment has led to efforts to develop instruments to reflect survivors’ needs accurately. However, evidence re
Risk and Consequences of CIT v2.1, Supplemental Findings, description of results from analyses within subgroups defined on cancer type and chemotherapy agent. (XLSX 327 kb)
